The American Cancer Society started a grant program to support early career clinicians aiming to become clinician scientists.
The Department of Defense Ovarian Cancer Research Program has released a pre-announcement for FY 2018 funding opportunities. Program Announcements are anticipated to be posted on Grants.gov in March 2018. Clinical Development Award Must be an independent investigator at or above the level of Assistant Professor (or equivalent). Supports the translation of promising preclinical findings into... […]
The American Association for Cancer Research has launched the AACR-Johnson & Johnson Lung Cancer Innovation Science Grants.
LUNGevity Foundation has issued a Request for Application for translational research in lung cancer for the 2018 Career Development Award.
As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.
The FY17 Defense Appropriations Act provides $10 million to the Department of Defense Kidney Cancer Research Program to support United States Army Medical Research Acquisition Activity. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program Research,... […]
The Neuroendocrine Tumor Research Foundation announced a new round of scientific and clinical research grants, aimed at advancing the treatment of and the search for cures to neuroendocrine tumors.
The Society for Translational Oncology Fellows' Forum is accepting applications through July 31.
The DOD prostate cancer program seeks to focus applications and direct funding on four “overarching challenges” and seven “focus areas” to address critical needs in prostate cancer research and clinical management.
Stand Up To Cancer announced a second SU2C Catalyst collaboration with Genentech, a member of the Roche Group, aimed at accelerating the development of new cancer treatments and combination therapies through clinical trials using Genentech medicines, including both commercial and pre-commercial treatments.